Article ID: 686366
Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia BSpark Therapeutics
Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer Inc. (NYSE:PFE), today announced that The New England Journal of Medicine has published interim data as of July 25, 2017, from the Phase 1/2 clinical trial of SPK-9001, an investigational gene therapy for hemophilia B.
Released:6-Dec-2017 5:00 PM EST
Article ID: 677863
Spark Therapeutics Announces Publication in The Lancet of Pivotal Phase 3 Clinical Trial Data for Investigational Voretigene NeparvovecSpark Therapeutics
Spark Therapeutics announces publication in The Lancet of pivotal Phase 3 data at year one for investigational voretigene neparvovec an investigational, potential one-time gene therapy candidate for the treatment of patients with vision loss due to confirmed biallelic RPE65-mediated inherited retinal disease (IRD).
Released:13-Jul-2017 6:30 PM EDT